J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer

被引：6
|
作者：
Gainor, Justin F. [1 ]
Shaw, Alice T. [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
来源：
LANCET | 2017年 / 390卷 / 10089期
关键词：
PROGRESSION-FREE; OPEN-LABEL; CHEMOTHERAPY; CERITINIB; SURVIVAL;
D O I：
10.1016/S0140-6736(17)31074-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [21] Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
    Tang, Hao
    Jin, Longyu
    Zhang, Zhang
    Jiang, Zhibin
    Malik, Zeeshan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M. J.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, R.
    Kim, D. -W.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Gupta, N.
    Haney, J.
    Kerstein, D.
    Popat, S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
  • [23] First-Line Crizotinib in ALK-Positive Lung Cancer
    Alkan, Ali
    Koksoy, Elif B.
    Utkan, Gungor
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 781 - 782
  • [24] Safety and efficacy of alectinib versus crizotinib in alk-positive non- small cell lung cancer: An update meta-analysis
    Xiong, Rui
    Fu, Haitan
    Zhang, Qianrui
    Li, Wei
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 36 (02) : 365 - 372
  • [25] Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
    Shaw, Alice Tsang
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Ahn, Jin Seok
    Ou, Sai-Hong Ignatius
    Pero, Maurice
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Rosell, Rafael
    Zeaiter, Ali Hassan
    Liu, Ting
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Brigatinib versus crizotinib for ALK-positive NSCLC
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (11): : E585 - E585
  • [27] Alectinib-a new chapter in the management of ALK-positive lung cancer
    Gainor, Justin F.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (03) : 343 - 346
  • [28] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
  • [29] Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.
    Shaw, Alice Tsang
    Peters, Solange
    Mok, Tony
    Gadgeel, Shirish M.
    Ahn, Jin Seok
    Ou, Sai-Hong Ignatius
    Perol, Maurice
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Rosell, Rafael
    Zeaiter, Ali Hassan
    Liu, Ting
    Golding, Sophie
    Balas, Bogdana
    Noé, Johannes
    Morcos, Peter N.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [30] Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
    Satoh, Hironori
    Okuma, Yusuke
    Kashima, Jumpei
    Konno-Yamamoto, Aya
    Yatabe, Yasushi
    Ohe, Yuichiro
    ONCOTARGETS AND THERAPY, 2021, 14 : 2911 - 2915
12345